SS
CCCC icon

SBI Securities’s C4 Therapeutics CCCC Stock Holding History

SBI Securities’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$476 Buy
102
+1
+1% +$3 ﹤0.01% 3049
2026
Q1 		$266 Buy
101
+1
+1% +$2 ﹤0.01% 3115
2025
Q4 		$191 Sell
100
-52
-34% -$123 ﹤0.01% 3225
2025
Q3 		$337 Buy
152
+2
+1% +$5 ﹤0.01% 3136
2025
Q2 		$215 Hold
150
– – ﹤0.01% 3285
2025
Q1 		$240 Hold
150
– – ﹤0.01% 3151
2024
Q4 		$540 Buy
+150
New +$746 ﹤0.01% 2864

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SBI Securities's CCCC Position: Q2 2026 in Review

SBI Securities increased its C4 Therapeutics (CCCC) stake by 0.99% in Q2 2026, buying an estimated $3 and bringing the position to 102 shares worth $476. The position accounts for ﹤0.01% of the portfolio, ranked #3049.

SBI Securities first reported a position in CCCC in Q4 2024 and has held it in 7 quarters since. The position peaked at $540 in Q4 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • SBI Securities held 102 shares of C4 Therapeutics worth $476 as of Q2 2026.
  • SBI Securities bought 1 C4 Therapeutics share in Q2 2026, an estimated $3.
  • C4 Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3049 holding.
  • SBI Securities first reported a position in C4 Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's C4 Therapeutics position peaked at $540 in Q4 2024.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.